Abstract
Objective
To evaluate trends in the incidence and survival of gynecologic carcinosarcoma over
the last 35 years and to explore ethnic disparities.
Study design
Using the Israeli National Cancer Registry database, all cases of gynecologic carcinosarcoma
were included (1980–2014). Age at diagnosis, patient’s ethnicity and anatomical site
were extracted. Age-standardized incidence rates (ASRs) were calculated for 3 time
periods (1980–1994, 1995–2004 and 2005–2014). Relative survival was calculated using
the Pohar-Perme method.
Results
Overall, 935 cases of gynecologic carcinosarcomas were diagnosed during 1980–2014.
The most common gynecologic anatomical site was the uterus (83.4%). Most cases (66%)
were diagnosed at ages 60–80, with median age of 69 years.
There was a steady increase in ASRs from 5.6 to 8.2 per million women. Throughout
1980–1994 and 2005–2014, ASRs were significantly higher in the Jewish compared to
the Arab population (5.8 vs. 3.1, p = 0.02 and 8.5 vs. 5.2, p = 0.002, respectively).
Relative survival rates increased throughout the study period. No significant differences
were noted in relative survival between the Jewish and Arab populations (p = 0.18).
Conclusion
The incidence of gynecologic carcinosarcoma increased significantly from 1980 through
2014. Nevertheless, survival rates increased during this time, with no difference
in survival between the Jewish and Arab populations.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Obstetrics and Gynecology and Reproductive BiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Ovarian and uterine carcinosarcomas: A comparative analysis of prognostic variables and survival outcomes.Int J Gynecol Cancer. 2010; 20: 888-894https://doi.org/10.1111/IGC.0b013e3181dc8292
- Uterine carcinosarcomas - Diagnosis and management.Oncol Res Treat. 2018; 41: 675-679https://doi.org/10.1159/000494335
- Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.Gynecol Oncol. 2005; 98: 274-280https://doi.org/10.1016/j.ygyno.2005.04.027
- Gynecologic cancer intergroup (GCIG) consensus review for uterine and ovarian carcinosarcoma.Int J Gynecol Cancer. 2014; 24: S55-S60https://doi.org/10.1097/IGC.0000000000000228
- Racial disparities in uterine and ovarian carcinosarcoma: A population-based analysis of treatment and survival.Gynecol Oncol. 2020; 157: 67-77https://doi.org/10.1016/j.ygyno.2020.01.017
- Population of Israel 2014–2005.Statistical. 2014; 143: 1-12
- Ethnic Disparities for Gynecologic Cancers in Israel.J Racial Ethn Heal Disparities. 2020; 7: 421-427https://doi.org/10.1007/s40615-019-00670-0
Fritz A, Percy C, Jack A, et al. International Classification of Diseases for Oncology (ICD-O)- 3rd Edition, 1st Revision.; 2013. doi:10.1016/s0031-3025(16)36112-8
Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ CK (eds). SEER Cancer Statistics Review 1975-2013 National Cancer Institute SEER Cancer Statistics Review 1975-2013 National Cancer Institute. SEER Cancer Stat Rev 1975-2013, Natl Cancer Institute Bethesda, MD, http//seer.cancer.gov/csr/1975_2013/, based Novemb 2015 SEER data submission, posted to SEER web site, April 2016. 2016.
- Cancer mortality for selected sites in 24 countries.Cancer Mortal Sel sites twenty four countries. 1969
HMD. Human Mortality Database. University of California, Berkeley (USA), and Max Planck Institute for Demographic Research (Germany).
R Core Team. R Development Core Team. R A Lang Environ Stat Comput. 2017. doi:http://www.R-project.org
Tomas J. Aragon Developer. epitools: Epidemiology Tools. R package version 0.5-7. https://CRAN.R-project.org/package=epitools. 2012.
Perme MP. relsurv: Relative Survival. R package version 2.1. https://CRAN.R-project.org/package=relsurv. 2017.
Ferguson SE, Tornos C, Hummer A, Barakat RR, Soslow RA. Prognostic features of surgical stage I uterine carcinosarcoma. Am J Surg Pathol. 2007. doi:10.1097/PAS.0b013e3181161ba3
- Surveillance, Epidemiology, and End Results analysis of 2677 cases of uterine sarcoma 1989–1999.Gynecol Oncol. 2004; 93: 204-208https://doi.org/10.1016/j.ygyno.2003.12.029
- Uterine carcinosarcoma: A review of the literature.Gynecol Oncol. 2015; 137: 581-588https://doi.org/10.1016/j.ygyno.2015.03.041
- Cancer of the corpus uteri.Int J Gynecol Obstet. 2018; 143: 37-50https://doi.org/10.1002/ijgo.12612
- Prevalence of obesity in Israel.Obesity Rev. 2005; 6: 115-116https://doi.org/10.1111/obr.2005.6.issue-210.1111/j.1467-789X.2005.00168.x
- Ethnicity-related trends in gynecologic malignancies in Israel, 1993–2013.Int J Gynecol Obstet. 2018; 142: 176-181https://doi.org/10.1002/ijgo.2018.142.issue-210.1002/ijgo.12524
- Trends of uterine carcinosarcoma in the united states.J Gynecol Oncol. 2018; 29https://doi.org/10.3802/jgo.2018.29.e22
- Prognostic factors impacting survival in early stage uterine carcinosarcoma.Gynecol Oncol. 2019; 152: 31-37https://doi.org/10.1016/j.ygyno.2018.10.034
- Adjuvant radiation therapy in uterine carcinosarcoma: A population-based analysis of patient demographic and clinical characteristics, patterns of care and outcomes.Gynecol Oncol. 2016; 141: 225-230https://doi.org/10.1016/j.ygyno.2016.02.013
- Prognostic factors for disease-free and overall survival of patients with uterine carcinosarcoma.Int J Clin Oncol. 2018; 23: 114-120https://doi.org/10.1007/s10147-017-1181-3
- Carcinosarcoma of the ovary, fallopian tube, and peritoneum: Prognostic factors and treatment modalities.Gynecol Oncol. 2016; 142: 248-254https://doi.org/10.1016/j.ygyno.2016.06.003
- The impact of multi-modal therapy on survival for uterine carcinosarcomas.Gynecol Oncol. 2010; 116: 419-423https://doi.org/10.1016/j.ygyno.2009.10.053
- Carcinosarcoma of the ovary.Brit J Cancer. 2003; 88: 654-657https://doi.org/10.1038/sj.bjc.6600770
- Carcinosarcoma of the ovary: A case-control study.Gynecol Oncol. 2011; 121: 477-481https://doi.org/10.1016/j.ygyno.2011.02.023
- A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.Gynecol Oncol. 2007; 107: 177-185https://doi.org/10.1016/j.ygyno.2007.07.070
- A comparison between different postoperative treatment modalities of uterine carcinosarcoma.Gynecol Oncol. 2005; 97: 166-170https://doi.org/10.1016/j.ygyno.2004.12.006
Odei B, Boothe D, Suneja G, Werner TL, Gaffney DK. Chemoradiation Versus Chemotherapy in Uterine Carcinosarcoma. Am J Clin Oncol. 2018. doi:10.1097/coc.0000000000000360
- Health in Israel: Patterns of equality and inequality.Social Sci Med. 1990; 31: 291-303https://doi.org/10.1016/0277-9536(90)90276-X
- Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: A SEER analysis.Gynecol Oncol. 2008; 111: 82-88https://doi.org/10.1016/j.ygyno.2008.05.016
Article info
Publication history
Published online: September 27, 2021
Accepted:
September 26,
2021
Received:
December 26,
2020
Identification
Copyright
© 2021 Elsevier B.V. All rights reserved.
